West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc.

WSTยทNYSE

$316.31

+1.3%
HealthcareMedical - Instruments & Supplies

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.

At a Glance

Live Snapshot
Market Cap$22.35B
EPS6.8300
P/E Ratio40.29
Earnings Date07/23/2026
3Y+7.0%
5Y+43.0%
10Y+104.0%
3Y-16.0%
5Y+43.0%
10Y+244.0%
3Y+4.0%
5Y+60.0%
10Y+244.0%
West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. Profit Bridge

WST ยท NYSE
Revenue3.07B
Cost of Goods Sold (1.97B)
Gross Profit1.10B
Operating Expenses (485.90M)
Operating Income617.40M
Interest Expense (600.00K)
Other Income/Expense-2.10M
Pretax Income615.30M
Income Tax (121.60M)
Net Income493.70M
Net Income
493.70M

Profitability Analysis

Gross Margin

35.9%

Strong gross margins indicate healthy pricing and efficient production or service delivery.

Operating Margin

20.1%

Healthy operating margins demonstrate effective cost control and strong business fundamentals.

Net Profit Margin

16.1%

Strong net margins indicate efficient operations and favorable tax/interest management.

Effective Tax Rate

19.8%

Moderate tax rate typical for most corporations. Represents standard tax burden on profits.

Profitability Insight

Efficient profit conversion: Minimal margin compression from gross to net indicates lean operations and favorable tax/interest environment.

West Pharmaceutical Services, Inc. Income Statement

WST โ€ข NYSE

West Pharmaceutical Services, Inc. Income StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011Dec 2010Dec 2009Dec 2008Dec 2007Dec 2006
REVENUE
3.1B
2.9B
3B
2.9B
2.8B
2.1B
1.8B
1.7B
1.6B
1.5B
1.4B
1.4B
1.4B
1.3B
1.2B
1.1B
1.1B
1.1B
1B
913.3M
GROSS PROFIT
(2B)
(1.9B)
(1.8B)
(1.7B)
(1.7B)
(1.4B)
(1.2B)
(1.2B)
(1.1B)
(1B)
(943.9M)
(973.8M)
(938.7M)
(878.6M)
(853.6M)
(787.1M)
(752.1M)
(748.5M)
(728.3M)
(651.5M)
1.1B
1B
1.1B
1.1B
1.2B
767.9M
608.8M
546.3M
514.8M
501M
454.1M
447.9M
429.5M
387.8M
339M
317.6M
303.6M
302.6M
291.8M
261.8M
OPERATING INCOME
(485.9M)
(407.6M)
(421.8M)
(375.4M)
(414.7M)
(348.9M)
(311.6M)
(291.5M)
(285.1M)
(285.5M)
(328.4M)
(266M)
(272.8M)
(251.3M)
(223.1M)
(211.6M)
(197.6M)
(178M)
(178.8M)
(156.1M)
(393.1M)
(338.5M)
(353.4M)
(316.9M)
(361.9M)
(302M)
(272.7M)
(262.9M)
(246M)
(239.8M)
(233M)
(228.7M)
(234.9M)
(218.1M)
(191.1M)
(187.7M)
(177.7M)
(159.3M)
(152.5M)
(144.8M)
(74.3M)
(69.1M)
(68.4M)
(58.5M)
(52.8M)
(46.9M)
(38.9M)
(40.3M)
(39.1M)
(36.8M)
(34.1M)
(37.3M)
(37.9M)
(33.2M)
(29.1M)
(23.9M)
(19.9M)
(18.7M)
(16.1M)
(11.1M)
617.4M
594.6M
710.9M
763.5M
758.7M
419M
297.2M
254.8M
229.7M
215.5M
125.7M
181.9M
156.7M
136.5M
115.9M
106M
106M
124.6M
113M
105.7M
PRE-TAX INCOME
(600K)
(2.9M)
(8.8M)
(7.6M)
(8.5M)
(8.5M)
(8M)
(8.1M)
(7.1M)
(6.4M)
(11.7M)
(19.5M)
(19.9M)
(14.5M)
(15M)
(13.6M)
(15.2M)
(16M)
(14.5M)
(12.7M)
17.1M
16.7M
19.2M
-2.5M
-7.5M
-7.1M
-4.2M
-6M
-5.8M
-5.3M
-10.1M
-16M
-18M
-12.7M
-13.7M
-13M
-14.4M
-14.6M
-8.5M
-10.6M
(18.5M)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
-11.7M
(0.0)
(8.9M)
(61.3M)
(0.0)
(0.0)
(0.0)
(2.9M)
(0.0)
(0.0)
(0.0)
-10.2M
(200K)
-2.1M
5.6M
4.8M
-62.9M
10.3M
-300K
3.5M
-6.5M
1.9M
-17.5M
-3.8M
-7.6M
-4.2M
-23.1M
-16.9M
-27.1M
-19.9M
-14.3M
-24.1M
-19.3M
615.3M
600.2M
715.7M
700.6M
769M
418.7M
300.7M
248.3M
231.6M
198M
121.9M
174.3M
152.5M
113.4M
99M
78.9M
86.1M
110.3M
88.9M
86.4M
NET INCOME
(121.6M)
(107.5M)
(122.3M)
(114.7M)
(107.2M)
(72.5M)
(59M)
(41.4M)
(80.9M)
(54.4M)
(26.3M)
(47.2M)
(40.2M)
(32.7M)
(23.5M)
(13.6M)
(13.5M)
(23.7M)
(17.2M)
(24.6M)
493.7M
492.7M
593.4M
585.9M
661.8M
346.2M
241.7M
206.9M
150.7M
143.6M
95.6M
127.1M
112.3M
80.7M
75.5M
65.3M
72.6M
86M
70.7M
67.1M

SEC Filings

WST - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

June 01, 2026
May 31, 2026
2026
8-K/A

8-K/A 2026 (Amended)

N/A

May 20, 2026
May 07, 2026
2026
8-K

8-K 2026

N/A

May 11, 2026
May 07, 2026
2026
8-K

8-K 2026

N/A

May 05, 2026
May 04, 2026
2026
10-Q

10-Q 2026 Q1

Q1

April 23, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

April 23, 2026
April 23, 2026
2026
DEF 14A

DEF 14A 2026

N/A

March 12, 2026
May 04, 2026
2026
8-K

8-K 2026

N/A

March 09, 2026
March 09, 2026
2026
10-K

10-K 2025 FY

FY

February 17, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 12, 2026
February 12, 2026
2026
Showing 1 to 10 of 524 filings